Skip to main content

Table 3 Literature Overview

From: Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates

Source

Period

Stage

AC

SCC

Sign.

AC - SCC

n

5y OS

n

5yOS

Early

 Hopkins et al. [4]

1970–1985

I

124

0.6

370

0.9

X

−0.3

 Shingleton et al. [30]

1984–1990

I

174

0.84

1136

0.84

 

0

 Couvreur et al.a

2005–2015

IA-1B1

20

1

52

0.89

 

0.11

 Teke et al. [8]

1996–2000

IA-IIB

33

0.77

218

0.73

 

0.04

 Ayhan et al. [31]

1980–1997

IB

67

0.84

454

0.88

 

− 0.04

 Eifel et al. [32]

1960–1989

IB

229

0.72

1538

0.81

X

− 0.09

 Nakanishi et al. [34]

1976–1995

IB

104

0.88

405

0.96

X

−0.08

 Galic et al. [3]

1998–2005

IB1

1094

0.85

3214

0.88

 

−0.03

 Shimada et al. [6]

1997–2003

IB1

184

0.92

258

0.95

 

−0.03

Advanced

 Galic et al. [3]

1998–2005

IB2

343

0.68

1701

0.69

 

−0.01

 Shimada et al. [6]

1997–2003

IB2

39

0.76

67

0.74

 

0.01

 Irie et al. [33]

1981–1996

IB-IIA

50

0.78

198

0.92

 

−0.14

 Shimada et al. [6]

1997–2003

IB-IIB

280

0.87

540

0.83

 

0.04

 Hopkins et al. [4]

1970–1985

II

40

0.47

186

0.62

X

−0.15

 Shingleton et al. [30]

1984–1990

II

102

0.57

1073

0.67

X

−0.11

 Galic et al. [3]

1998–2005

IIA

202

0.46

1488

0.58

X

−0.13

 Shimada et al. [6]

1997–2003

IIA

11

0.55

83

0.87

X

−0.33

 Galic et al. [3]

1998–2005

IIB

424

0.46

3754

0.55

X

−0.09

 Katanyoo et al. [7]

1980–1997

IIB

85

0.72

170

0.71

 

0.01

 Shimada et al. [6]

1997–2003

IIB

46

0.63

132

0.79

X

−0.16

 Couvreur et al.a

2005–2015

IB2-IVA

16

0.88

91

0.63

 

0.25

 Hopkins et al. [4]

1970–1985

III

25

0.08

114

0.36

X

−0.28

 Shingleton et al. [30]

1984–1990

III

47

0.3

672

0.4

 

−0.1

 Galic et al. [3]

1998–2005

IIIA

80

0.16

695

0.34

X

−0.18

 Galic et al. [3]

1998–2005

IIIB

238

0.2

2568

0.31

X

−0.11

 Katanyoo et al. [7]

1995–2008

IIIB-IVA

56

0.41

112

0.47

 

−0.06

 Shingleton et al. [30]

1984–1990

IV

41

0.05

287

0.13

 

−0.08

 Galic et al. [3]

1998–2005

IVA

82

0.08

622

0.17

 

−0.09

 Galic et al. [3]

1998–2005

IVB

281

0.09

959

0.06

 

0.04

  1. AC adenocarcinoma, SCC Squamous cell carcinoma, n number, 5yOS 5 year overall survival period: years of enrollment of patients, Sign significance with p-value < 0.05 (all significance levels lie between 0.01 and 0.05); AC-SCC: 5y survival data AC minus 5y survival data SCC resulting in a delta value
  2. acurrent article